Screening for Comorbid Conditions Not Adequate in Acromegaly
Less than half of the participants had screening reported for sleep apnea, cardiomyopathy, and colon polyps.
Individuals with acromegaly in the Somatuline® (lanreotide) Depot for Acromegaly (SODA) registry were not widely screened for associated comorbidities, despite the increased mortality and disease burden that results from such coexisting comorbidities, according to a study published in Endocrine.
The SODA registry (ClinicalTrials.gov Identifier: NCT00686348) is a multicenter, post-marketing, observational study that was previously used to assess the safety, efficacy, and convenience of lanreotide depot for the treatment of acromegaly. The current analysis sought to summarize the frequency of comorbidity screenings using data from this registry. This 2-year dataset included 241 patients with acromegaly as of September 29, 2014. Data collected and analyzed included insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with and without diabetes, glycated hemoglobin levels, colonoscopies, gallbladder sonographies, echocardiograms, sleep studies, and pituitary hormone deficiencies.
At enrollment in the SODA registry, 18.7% of participants reported gallbladder sonographies (17.8% had gallstones), 29.9% reported sleep studies (79.2% had sleep apnea), 46.1% reported echocardiograms (46.8% abnormal), and 48.1% reported colonoscopies (35.3% had polyps). Follow-up data on glycated hemoglobin levels were only reported in 30.8% of participants at 1 year, and 41.2% at 2 years, and levels were similar at each point for participants both with and without diabetes. Fewer participants with diabetes achieved IGF-1 below the upper limit of normal range at 2 years compared with participants without diabetes (58.3% vs 80.6%; P=.033). Pituitary hormone deficiencies were reported more frequently by men than women at the time of enrollment (P<.001).
Study investigators conclude, “this analysis of acromegaly patients from the observational SODA registry found less frequent real-life monitoring of comorbid conditions than recommended by recent treatment guidelines. Additional prospective analysis will be needed to further identify and address potential barriers to managing acromegaly-associated comorbidities and the impact of screening on survival.”
This study was funded by Ipsen Biopharmaceuticals, Inc.
Woodmansee WW, Gordon MB, Molitch ME, et al. Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis [published online May 16, 2018]. Endocrine. doi: 10.1007/s12020-018-1615-3